The chronic myeloid leukemia treatment ‘Sprycel tab (dasatinib, BMS Korea)’ has received the green light to expand its reimbursement.

The Health Insurance Review and Assessment Service announced that it had set the reimbursement standards for Sprycel in pediatric patients with acute lymphoblastic leukemia (ALL) at the 5th Cancer Disease Deliberation Committee meeting that was held on the 18th.

Based on the set standards, Sprycel can now progress to the next step in expanding its reimbursement to the indication set above. The drug will now undergo Drug Reimbursement Evaluation Committee review, drug pricing negotiation with the National Health Insurance Service, then receive final deliberat